The novel oral gonadotropin-releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles.
The novel oral gonadotropin-releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles.
复制标题
DOI：
10.1002/rmb2.12448
复制
发表时间：
2022-01
影响因子：
3.4
通讯作者：
Okada H
中科院分区：
文献类型：
--
作者：
Komiya S;Tsuzuki-Nakao T;Asai Y;Inoue T;Morimoto Y;Okada H
Relugolix是一种口服促性腺激素释放激素拮抗剂（GnRHant），于2019年首次引入。本研究调查了传统注射型GnRHant制剂和这种新的口服GnRHant制剂对控制性卵巢刺激（COS）周期的影响。Relugolix给药126个周期，常规GnRHant注射给药658个周期（对照）。通过拮抗剂方法进行卵泡刺激，对于最终卵母细胞成熟，选择重组人绒毛膜促性腺激素（rHCG）或促性腺激素释放激素激动剂（GnRHa）或两者（双触发剂）。计数回收的卵母细胞的数量，然后评价它们的后续发育直至卵裂阶段。作为本研究主要结局的获卵数受GnRHant类型和最终卵母细胞成熟剂组合的影响。Relugolix与GnRHa触发剂联合治疗显示，获卵数显著低于其他联合治疗（p < 0.001）。Relugolix是COS周期的新选择，但应谨慎与最终成熟剂联合使用。本研究经Medical Corporation Sankeikai机构伦理委员会批准后进行（批准编号：2019 - 34）。
Relugolix is an oral gonadotropin‐releasing hormone antagonist (GnRHant), which was first introduced in 2019. This study investigated the effects of the conventional injectable GnRHant formulation and this new oral GnRHant formulation on controlled ovarian stimulation (COS) cycles. Relugolix was administered in 126 cycles and conventional GnRHant injection was administered in 658 cycles (controls). The follicle stimulation was performed by an antagonist method, and for final oocyte maturation, recombinant human chorionic gonadotropin (rHCG), or gonadotropin‐releasing hormone agonist (GnRHa), or both (dual trigger) were selected. The number of retrieved oocytes was counted and then they were evaluated for subsequent development up to cleavage stage. The number of retrieved oocytes which was the primary outcome of this research was affected by the combination of GnRHant type and the final oocyte maturation agent. The combination of relugolix and a GnRHa trigger showed a significantly lower number of retrieved oocytes (p < 0.001) than the other combinations. Relugolix is a new option for COS cycles, but should be carefully combined with the final maturation agent. This study was conducted after approval by the Medical Corporation Sankeikai Institutional Ethics Committee (approval number: 2019‐34).
登录
查看更多内容
流行病学和临床研究中缺少数据的多重归因：潜力和陷阱。
DOI：
10.1136/bmj.b2393
发表时间：
2009-06-29
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Sterne JA;White IR;Carlin JB;Spratt M;Royston P;Kenward MG;Wood AM;Carpenter JR
通讯作者：
Carpenter JR
影响因子：
3.4
作者：
Nakao K;Kuroda K;Horikawa T;Moriyama A;Juen H;Itakura A;Watanabe H;Takamizawa S;Ojiro Y;Nakagawa K;Sugiyama R
通讯作者：
Sugiyama R
影响因子：
6.1
作者：
Haas, J.;Bassil, R.;Casper, R. F.
通讯作者：
Casper, R. F.
影响因子：
11.5
作者：
Markham, Anthony
通讯作者：
Markham, Anthony
影响因子：
5.8
作者：
HOFF, JD;QUIGLEY, ME;YEN, SSC
通讯作者：
YEN, SSC